These SCFAs tell special cells in your gut (called L-cells) to release more GLP-1
expected to reopen overnight after water main repairs
[1] [2] These medications work by mimicking the action of naturally occurring GLP-1 hormone, which stimulates insulin secretion in response to meals, suppresses glucagon release, slows gastric emptying, and promotes satiety
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
This must be evaluated within the broader clinical context of metabolic benefitfertility windowdiscontinuation risk management (98)
(2024, September) Retatrutide is a novel triple-agonist targeting GLP-1, GIP, and glucagon receptors, showing in phase 2 trials that it can deliver remarkably large weight losses (up to ~24% over 48 weeks in people with obesity) along with strong improvements in HbA1c, lipid profiles, liver fat (in NAFLD), insulin sensitivity, and other cardiometabolic markers